At least 12 groups have been identified, including groups A, B, C, X, Y and W. The pattern of disease caused by each group varies by time and country or geographical areas. Vaccines work by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against a disease. Doit-il être proposé systématiquement à tous les parents ? Trade marks are owned by or licensed to the GSK group of companies. In fact, it can lead to death.9, BEXSERO demonstrated serum bactericidal activity against three strains selected to measure one of three vaccine antigens prevalent among strains in the U.S.1,*, *Immune response data were recorded for antigens fHbp, NadA, and PorA P1.4. In case you would like to receive SMS-reminders for the event you have registered, please scroll down to provide your mobile number. Infolettre 194 / 8 octobre 2020 3 / 3 ANNEXE 1 – Dénominations communes, noms et codes de produits des vaccins du PQI Dénomination commune Nom du vaccin Code de produit fictif Vaccin contre la diphtérie, la coqueluche et le tétanos (dcaT) Adacel 99113787 Vaccin meningococcique Bexsero … The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed. 2mois) qui ont reçu BEXSERO.Parmi les sujets qui ont reçu BEXSERO, on dénombrait 4843nourrissons et enfants (âgés de moins de 2ans), 1503adolescents (âgésde 11 à 17ans)et 1180adultes (âgés de plus de 17ans), respectivement. 4 L’avis, paru au Journal officiel le 18 décembre, annonce un prix public de 90,08 euros TTC la dose pour Bexsero®. /content/cf-pharma/health-hcpportal/en_US/hcp/home, BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by, BEXSERO is contraindicated in cases of hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO, Appropriate observation and medical treatment should always be readily available in case of an anaphylactic reaction following the administration of the vaccine, The tip caps of the prefilled syringes contain natural rubber latex, which may cause allergic reactions, Syncope (fainting) can occur in association with administration of BEXSERO. Do you know how to talk to your patients and their parents? Event registration completed - pending validation. 1 … You now have sucesfully register for the event and you can also access the latest updates, events and resources. You now have access to the latest updates, events and resources. Watch the commercial, share it with friends, then discover more great BEXSERO TV commercials on iSpot.tv Please modify your settings or use a different browser to continue. However, a suitable strain for assessing immune response was not available for component NHBA.1. As for all medicines, data on the use of Bexsero are continuously monitored. The study showed that Bexsero was effective at stimulating an immune response to N. meningitidis group B and that two doses were needed to produce an adequate immune response. More detail is available in the summary of product characteristics, 02/07/2020 Bexsero - EMEA/H/C/002333 - II/0091. Ensure procedures are in place to avoid injury from falling associated with syncope, The most common solicited adverse reactions observed in clinical trials were pain at the injection site (≥83%), myalgia (≥48%), erythema (≥45%), fatigue (≥35%), headache (≥33%), induration (≥28%), nausea (≥18%), and arthralgia (≥13%), Vaccination with BEXSERO may not provide protection against all meningococcal serogroup B strains, Some individuals with altered immunocompetence may have reduced immune responses to BEXSERO, Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by, Vaccination with BEXSERO may not result in protection in all vaccine recipients. lundi 28 décembre 2020 16:55; Abécédaire des questions-réponses les plus fréquentes sur la vaccination COVID-19. Nom de l'auteur Fanny Consultations Vu 101 fois Nombre de réponses 1 réponse Thème Mes remboursements Il y a 4 mois Date 2 septembre 2020 question q. Répondre à cette question; Réponses Changes since initial authorisation of medicine, Initial marketing-authorisation documents, International non-proprietary name (INN) or common name, Anatomical therapeutic chemical (ATC) code, Date of issue of marketing authorisation valid throughout the European Union, outer membrane vesicles from neisseria meningitidis group b (strain nz 98/254), recombinant Neisseria meningitidis group B fHbp fusion protein, recombinant Neisseria meningitidis group B NadA protein, recombinant Neisseria meningitidis group B NHBA fusion protein, Annex IIA - Manufacturing-authorisation holder responsible for batch release. Published by MIMS September 2020 Au nombre des nourrissons qui ont fait Paris (France) ; 2019 [consulté le 2 octobre 2020] Recommandations sanitaires pour les voyageurs 2020. The first main study involved 2,627 children who were two months old when the study started. Trademarks are owned by or licensed to the GSK group of companies. NEW Of the subjects who received primary infant series of Bexsero, 3285 received a booster dose in the second year of life. Il est indispensable de mettre ses vaccins à jour tout au long de sa vie pour être protégé efficacement et durablement. Invasive disease occurs when the bacteria spread through the body causing serious infections such as meningitis (infection of the membranes that surround the brain and spine) and septicaemia (blood infection). Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B. In the meantime, you can enjoy the public content on our website. Contributeur débutant. Y a-t-il une indication à le faire après 12 mois et selon quel schéma ? Side effects reported with Bexsero are carefully evaluated and any necessary action taken to protect patients. meningococcal group B vaccine (recombinant, component, adsorbed). The studies measured the production of protective antibodies which are able to kill the bacteria. Your account has been activated successfully, but we still need to validate you as a healthcare professional. The European Medicines Agency decided that Bexsero’s benefits are greater than its risks and it can be authorised for use in the EU. The impact of invasive disease in different age groups as well as the variability of antigen epidemiology for group B strains in different geographical areas should be considered when vaccinating. In addition, a single booster dose of Bexsero at 12 months of age produced a stronger immune response in children who had already received Bexsero than the first of two ‘catch-up’ doses in children of the same age who had not. Le vaccin Bexsero serait, selon Novartis, « le premier vaccin à large spectre » contre la méningite B. Il couvre 70 à 90 % des souches de méningocoques B dans les pays d’Europe. Bexsero should be used according to official recommendations. To report SUSPECTED ADVERSE REACTIONS, contact GSK at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. La méningite la plus fréquente est la méningite B et c'est seulement depuis 2014 qu'un vaccin, le Bexsero, est disponible. BEH Hors série du 19 mai 2020. Remboursement Bexsero Remboursez-vous le vaccin Bexsero pour les bébés ? When the person is then exposed to the bacterium, these antibodies together with other components of the immune system will be able to kill the bacteria and help protect against the disease. Bexsero recipients, 6837 were infants and children (less than 2 years of age), 1051 were children (2 to 10 years of age) and 2677 were adolescents and adults. EMA is in the process of making appropriate changes to this website. Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. Hear from a physician who has seen the disease first-hand. Saint–Maurice (France) ; 2020 [consulté le 2 octobre 2020] For more information about using Bexsero, see the package leaflet or contact your doctor or pharmacist. Selon quel schéma recommandez-vous de la faire si vaccination avant 12 mois ? The most common side effects with Bexsero in children up to 10 years of age (seen in more than 1 patient in 10) are eating disorders, sleepiness, unusual crying, headache, diarrhoea, vomiting, rash, arthralgia (joint pain), fever and irritability as well as tenderness, swelling, hardness and redness of the skin at the injection site. This site requires JavaScript to be enabled to work properly. Le délai de remboursement de la mutuelle Gras Savoye Vous serez remboursé dans un délai de 48h / rapidement, dès réception par Gras Savoye du décompte de remboursement de votre régime obligatoire (souvent la Sécurité sociale). Cette maladie mortelle, touche majoritairement de jeunes patients. Quelles sont les recommandations pour le bexsero ? BEXSERO is an FDA-approved vaccine to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years. BEXSERO pre-filled syringe without needle (AUST R 190718) BEXSERO pre-filled syringe with needle (AUST R 190719) This leaflet was prepared on 31 March 2020. The vaccine is ‘adsorbed’. When given concomitantly with other vaccines, BEXSERO should be administered at a different injection site. Young children are most at risk, followed by adolescents. Bexsero contains parts of the bacteria N. meningitidis group B. Bexsero is available as a suspension for injection in a pre-filled syringe and can only be obtained with a prescription. Please update your operating system or use a different device. Le vaccin BEXSERO à constituants multiples contre le méningocoque B (recombinant, adsorbé) sert à prévenir la méningococcie causée par la bactérie Neisseria meningitidis du groupe B chez les personnes âgées de 2 mois à 25 ans. BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years. For the full list of side effects and restrictions with Bexsero, see the package leaflet. Solicited Adverse Reactions 3+1 Infant Schedule This vaccine contains four common strains of group B meningococcal bacteria. 8 janvier 2015 Docteur Boucherat Médicament Commentaires fermés sur Remboursement de BEXSERO. GSK is not responsible for content on third-party websites.
Samsung A20s Prix Algérie,
Page De Garde Cahier Latin,
Dacia Occasion Réunion,
E Learning Paris 1,
Beau-papa'', Vianney Histoire,
Prix Concert Johnny Hallyday Stade De France,
George Balanchine épouses,
Renault Reinastella 2038,
Vos Déclarations De Revenus,
Mon Premier Larousse Illustré,